Javascript must be enabled to continue!
In silico identification of vaccine targets for 2019-nCoV
View through CrossRef
Background:
The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China.
Methods:
The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0.
Results:
We report
in silico
identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a
de novo
search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential.
Conclusions:
Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Title: In silico identification of vaccine targets for 2019-nCoV
Description:
Background:
The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat.
According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China.
Methods:
The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides.
The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.
Results:
We report
in silico
identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development.
First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays.
Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB).
Lastly, we conducted a
de novo
search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential.
Conclusions:
Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Related Results
In silico elucidation revealed SARS CoV and MERS CoV Drug Compounds could be Potential Therapeutic Candidates against Post Fusion Core (S2) Protein of Novel Coronavirus (2019-nCov)
In silico elucidation revealed SARS CoV and MERS CoV Drug Compounds could be Potential Therapeutic Candidates against Post Fusion Core (S2) Protein of Novel Coronavirus (2019-nCov)
Abstract
Novel coronavirus (2019-nCoV), since its emergence from Wuhan China in December 31, 2019 is still uncontrolled and has raised attention around the globe. According...
Screening and Detection SARS-CoV-2RNA from Buffy Coats v1
Screening and Detection SARS-CoV-2RNA from Buffy Coats v1
The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
Simulating the Infected Population and Spread Trend of 2019-nCov Under Different Policy by EIR Model (EIR模型模拟不同政策下2019-nCov的感染人口和传播趋势)
Simulating the Infected Population and Spread Trend of 2019-nCov Under Different Policy by EIR Model (EIR模型模拟不同政策下2019-nCov的感染人口和传播趋势)
<b>English Abstract:</b> Background: Chinese government has taken strong measures in response to the epidemic of new coronavirus (2019-nCoV) from Jan.23, 2020. The numb...
In-silico Immunomodelling of 2019-nCoV
In-silico Immunomodelling of 2019-nCoV
Abstract
Background: Novel Corona Virus 2019 (2019-nCoV) is a positive-sense single-strand RNA virus form coronaviridae family, responsible for corona virus infectious dise...
Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Abstract
Background
Responding to SARS-CoV-2 Delta variants escaped the vaccine-induced immunity and waning immunity from the i...
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
ABSTRACT
This article is aim to investigate the safety and immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster in pat...
Screening and Detection SARS-CoV-2RNA from Buffy Coats v1
Screening and Detection SARS-CoV-2RNA from Buffy Coats v1
This SOP has been developed to minimize or eliminate employee occupational exposure to SARS-CoV-2 virus from blood samples of healthy volunteers obtained from the New York Center (...

